Prakt. lékáren. 2010; 6(3): 119-124

Immunomodulators of microbial origin

PharmDr.Petr Jílek, CSc.
Katedra biologických a lékařských věd, Farmaceutická fakulta v Hradci Králové, Univerzita Karlova v Praze

Microbiota is crucial, permanent stimulus of immunity. Modified microbes or components of their bodies could be used for efficient

modulation of immune reactions. In addition to vaccines, which induce specific responses, immunomodulators providing less specific

effect could be used. The aim of such agents is a support of antimicrobial immunity in general as well as stimulation of effectors of anticancer

immunity. Contemporary gnose enables elucidate mode of actions of microbial modulators, clinical studies prove usable effect.

For applications in oncology are indicated BCG vaccine, muramylpeptides and glucans, for prevention of respiratory and urinary tract

infection polybacterial immunomodulators. All these agents are described in detail and their therapeutic values are discussed.

Keywords: stimulation of innate immunity, BCG vaccine, muramylpeptides, glucans, polybacterial immunomodulators, receptors PRR,

Published: June 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jílek P. Immunomodulators of microbial origin. Praktické lékárenství. 2010;6(3):119-124.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ariga T. Gene therapy for primary immunodeficiency diseases: recent progress and misgi-vings. Curr Pharm Des. 2006; 12: 549-556. Go to original source... Go to PubMed...
    2. Breman JG, Arita I. The confirmation and maintenance of smallpox eradication. N Engl J Med. 1980; 303: 1263-1273. Go to original source... Go to PubMed...
    3. Obregon R, Chitnis K, Morry C, Feek W, Bates J, Galway M, Ogden E. Achieving polio eradication: a review of health communication evidence and lessons learned in India and Pakistan. Bull WHO. 2009; 87: 624-630. Go to original source... Go to PubMed...
    4. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991-1045. Go to original source... Go to PubMed...
    5. Chedid L, Lamensans A, Parant F, Parant M, Adam A, Petit JF, Lederer E. Protective effects of delipidated mycobacterial cells and purified cell walls against Ehrlich carcinoma and a syngeneic lymphoid leukemia in mice. Cancer Res 1973; 33: 2187-2195.
    6. Conti-Freitas LC, Foss-Freitas MC, Mamede RCM, Foss NT. Effect of BCG stimulus on proin-flammatory cytokine production in laryngeal cancer. Cancer Immunol Immunother. 2009; 58: 25-29. Go to original source... Go to PubMed...
    7. Bottomley A, Debruyne C, Felip E, Millward M, Thiberville L, D'Addario G, Rome L, Zatloukal P, Coens C, Giaccone G. Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer. Eur J Cancer. 2008; 44: 2178-2184. Go to original source... Go to PubMed...
    8. Uyl-de Groot CA, Vermorken JB, Hanna MG, Jr., Verboom P, Groot MT, Bonsel GJ, Meijer CJLM, Pinedo HM. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine. 2005; 23: 2379-2387. Go to original source... Go to PubMed...
    9. Parant M, Parant F, Vinit MA, Jupin C, Noso Y, Chedid L. Priming effect of muramyl peptides for induction by lipopolysaccharide of tumor necrosis factor production in mice. J Leukocyt Biol. 1990; 47: 164-169. Go to original source... Go to PubMed...
    10. Darcissac EC, Bahr GM, Pouillart PR, Riveau GJ, Parant MA. Selective potentiation of cytokine expression in human whole blood by murabutide, a muramyl dipeptide analogue. Cytokine. 1996; 8: 658-666. Go to original source... Go to PubMed...
    11. Yang S, Tamai R, Akashi S, Takeuchi O, Akira S, Sugawara S, Takada H. Synergistic effect of muramyldipeptide with lipopolysaccharide or lipoteichoic acid to induce inflammatory cytokines in human monocytic cells in culture. Infect Immun. 2001; 69: 2045-2053. Go to original source... Go to PubMed...
    12. Asano T, McIntyre BW, Bednarczyk JL, Wygant JN, Kleinerman ES. Liposomal muramyl tripeptide upregulates adhesion molecules on the surface of human monocytes. Oncol Res. 1995; 7: 253-257.
    13. Galligioni E, Favaro D, Santarosa M, Quaia M, Spada A, Freschi A, Alberti D. Induction and maintenance of monocyte cytotoxicity during treatment with liposomes containing muramyl tripeptide despite tachyphylaxis to the cytokine response. Clin Cancer Res. 1995; 1: 493-499.
    14. Sosnowska D, Mysliwski A, Dzierzbicka K, Kolodziejczyk AM. The in vitro effect of new muramyl peptide derivatives on cytotoxic activity of NK (natural killer) cells from hamsters bearing Ab Bomirski melanoma. Biotherapy. 1997; 10: 161-168. Go to original source... Go to PubMed...
    15. Athie-Morales V, O'Connor GM, Gardiner CM. Activation of human NK cells by the bacterial pathogen-associated molecular pattern muramyl dipeptide. J Immunol. 2008; 180: 4082-4089. Go to original source... Go to PubMed...
    16. Hornung RL, Longo DL, Gowda VL, Kwak LW. Induction of a CD8+ cytotoxic T lymphocyte response to soluble antigen given together with a novel muramyl dipeptide adjuvant, N-acetyl-D-glucosaminyl-(beta 1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine (GMDP). Therap Immunol. 1995; 2: 7-14.
    17. Tamura M, Yoo YC, Yoshimatsu K, Yoshida R, Oka T, Ohkuma K, Arikawa J, Azuma I. Effects of muramyl dipeptide derivatives as adjuvants on the induction of antibody response to recombinant hepatitis B surface antigen. Vaccine. 1995; 13: 77-82. Go to original source... Go to PubMed...
    18. Anonym. Mifamurtide: CGP 19835, CGP 19835A, L-MTP-PE, liposomal MTP-PE, MLV 19835A, MTP-PE, muramyltripeptide phosphatidylethanolamine. Drugs R D. 2008; 9: 131-135. Go to original source... Go to PubMed...
    19. Meyers PA. Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma. Expert Rev Anticancer Ther. 2009; 9: 1035-1049. Go to original source... Go to PubMed...
    20. Amati L, Pepe M, Passeri ME, Mastronardi ML, Jirillo E, Covelli V. Toll-like receptor signaling mechanisms involved in dendritic cell activation: potential therapeutic control of T cell polarization. Curr Pharm Des. 2006; 12: 4247-4254. Go to original source... Go to PubMed...
    21. van Bruggen R, Drewniak A, Jansen M, van Houdt M, Roos D, Chapel H, Verhoeven AJ, Kuijpers TW. Complement receptor 3, not Dectin-1, is the major receptor on human neutrophils for beta-glucan-bearing particles. Mol Immunol. 2009; 47: 575-581. Go to original source... Go to PubMed...
    22. Kimura Y, Tojima H, Fukase S, Takeda K. Clinical Evaluation of Sizofilan as Assistant Immu-notherapy in Treatment of Head and Neck Cancer. Acta Otolaryngol Suppl 1994: 192-195. Go to original source... Go to PubMed...
    23. Mashiko H, Satoh J, Hatayama H, Kitamura H. A case of advanced gastric cancer with liver metastasis completely responding to a combined immunochemotherapy with UFT, mi-tomycin C and lentinan. Gan to Kagaku Ryoho (Jap J Cancer Chemother) 1992; 19: 715-718.
    24. Suto T, Fukuda S, Moriya N, Watanabe Y, Sasaki D, Yoshida Y, Sakata Y. Clinical study of biological response modifiers as maintenance therapy for hepatocellular carcinoma. Cancer Chemother Pharmacol 1994; 33(Suppl): S145-148. Go to original source... Go to PubMed...
    25. Gu Y-H, Takagi Y, Nakamura T, Hasegawa T, Suzuki I, Oshima M, Tawaraya H, Niwano Y. Enhancement of radioprotection and anti-tumor immunity by yeast-derived beta-glucan in mice. J Med Food. 2005; 8: 154-158. Go to original source... Go to PubMed...
    26. Tohamy AA, El-Ghor AA, El-Nahas SM, Noshy MM. Betaglucan inhibits the genotoxicity of cyclophosphamide, adriamycin and cisplatin. Mut Res. 2003; 541: 45-53. Go to original source... Go to PubMed...
    27. Patchen ML, Vaudrain T, Correira H, Martin T, Reese D. In vitro and in vivo hematopoietic activities of Betafectin PGGglucan. Exp Hematol. 1998; 26: 1247-1254. Go to PubMed...
    28. Dritz SS, Shi J, Kielian TL, Goodband RD, Nelssen JL, Tokach MD, Chengappa MM, Smith JE, Blecha F. Influence of dietary beta-glucan on growth performance, nonspecific immuni-ty, and resistance to Streptococcus suis infection in weanling pigs. J Animal Sci. 1995; 73: 3341-3350. Go to original source... Go to PubMed...
    29. Rice PJ, Adams EL, Ozment-Skelton T, Gonzalez AJ, Goldman MP, Lockhart BE, Barker LA, Breuel KF, Deponti WK, Kalbfleisch JH, et al. Oral delivery and gastrointestinal absorption of soluble glucans stimulate increased resistance to infectious challenge. J Pharmacol Experiment Therap. 2005; 314: 1079-1086. Go to original source... Go to PubMed...
    30. Isoda N, Eguchi Y, Nukaya H, Hosho K, Suga Y, Suga T, Nakazawa S, Sugano K. Clinical efficacy of superfine dispersed lentinan (beta-1,3-glucan) in patients with hepatocellular carcinoma. Hepato-Gastroenterology 2009, 56: 437-441. Go to PubMed...
    31. Shimizu K, Watanabe S, Watanabe S, Matsuda K, Suga T, Nakazawa S, Shiratori K. Efficacy of oral administered superfine dispersed lentinan for advanced pancreatic cancer. Hepato-Gastroenterology 2009; 56: 240-244. Go to PubMed...
    32. Hazama S, Watanabe S, Ohashi M, Yagi M, Suzuki M, Matsuda K, Yamamoto T, Suga Y, Suga T, Nakazawa S, et al. Efficacy of orally administered superfine dispersed lentinan (beta-1,3-glucan) for the treatment of advanced colorectal cancer. Anticancer Res 2009; 29: 2611-2617.
    33. Yamada J, Hamuro J, Hatanaka H, Hamabata K, Kinoshita S. Alleviation of seasonal allergic symptoms with superfine beta-1,3-glucan: a randomized study. J Allerg Clin Immunol. 2007; 119: 1119-1126. Go to original source... Go to PubMed...
    34. Kirmaz C, Bayrak P, Yilmaz O, Yuksel H. Effects of glucan treatment on the Th1/Th2 balance in patients with allergic rhinitis: a double-blind placebo-controlled study. Eur Cytokine Netw. 2005; 16: 128-134.
    35. Dolezalova K, Kuralova Z. Bacterial autovaccine therapy in children with respiratory allergy in early childhood. Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove Suppl. 1976; 19: 599-601.
    36. Riglova J, Jirkal J. Preliminary experiences with the combined autovaccine and polyvalent vaccine. Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove. 1968; 11: 659-664. Go to PubMed...
    37. Debbas N, Derenne JP. Preventive effects of an immunostimulating product on recurrent infections of chronic bronchitis in the elderly. Lung 1990; 168(Suppl): 737-740. Go to original source... Go to PubMed...
    38. Idohou N, Couderc R, Rocharveiller M, Tallet F, Giroud JP, Raichvarg D. The Immunomodula-ting Agent RU 41740 Complexed with Very-Low- Density Lipoproteins Enhances Human Polymorphonuclear Neutrophil Oxidative Metabolism Invitro. Pharmacology 1993; 46: 341-345. Go to original source... Go to PubMed...
    39. HbabiHaddioui L, Roques C. Inhibition of Streptococcus pneumoniae adhesion by specific salivary IgA after oral immunisation with a ribosomal immunostimulant. Drugs 1997; 54: 29-32. Go to original source... Go to PubMed...
    40. Nimier K, Wolff F, Allouch PY, Guy-Grand D, Bloy C. Protective effects of RU 41740, a bacterial immunomodulator, against experimental infections: induction of cytokine and immunoglobulin release in mice after oral administration. Int J Immunopharmacol. 1999; 21: 561-574. Go to original source... Go to PubMed...
    41. Mimouni J, Ramsteiner A, Fontanges R. In vivo study of the immunomodulating activity of OM-85 using the plaque-forming cells technique (PFC) in mice. Int J Immunopharmacol. 1995; 17: 787-792. Go to original source... Go to PubMed...
    42. Huber M, Mossmann H, Bessler WG. Th1-orientated immunological properties of the bacterial extract OM-85-BV. Eur J Med Res. 2005; 10: 209-217.
    43. Nikolova M, Stankulova D, Taskov H, Nenkov P, Maximov V, Petrunov B. Polybacterial immu-nomodulator Respivax restores the inductive function of innate immunity in patients with recurrent respiratory infections. Internat Immunopharmacol. 2009; 9: 425-432. Go to original source... Go to PubMed...
    44. Aloui R, Gormand F, Guibert B, Corallo F, Fayolle MP, Pacheco Y. RU 41740 (Biostim (R)) stimulates the production of granulocyte macrophage colony-stimulating factor and interleukin-8 by human bronchial epithelial cells in vitro. Gen Pharmacol. 1996; 27: 1351-1353. Go to original source... Go to PubMed...
    45. Keul R, Roth M, Papakonstantinou KE, Nauck M, Perruchoud AP, Block LH. Induction of inter-leukin 6 and interleukin 8 expression by Broncho-Vaxom (OM-85 BV) via C-Fos/serum responsive element. Thorax 1996; 51: 150-154. Go to original source... Go to PubMed...
    46. Lanzilli G, Falchetti R, Cottarelli A, Macchi A, Ungheri D, Fuggetta MP. In vivo effect of an im-munostimulating bacterial lysate on human B lymphocytes. Int J Immunopathol Pharmacol. 2006; 19: 551-559. Go to original source... Go to PubMed...
    47. Portales P, Clot J. Immunostimulants revisited: focus on the pharmacology of Ribomunyl. Biodrugs 2006; 20: 81-84. Go to original source... Go to PubMed...
    48. Berber A, Del-Rio-Navarro B. Compilation and meta-analysis of randomized placebo-controlled clinical trials on the prevention of respiratory tract infections in children using immunostimulants. J Invest Allergol Clin Immunol 2001; 11: 235-246.
    49. Del-Rio-Navarro BE, Espinosa Rosales F, Flenady V, Sienra-Monge JJL. Immunostimulants for preventing respiratory tract infection in children. Cochrane Database Syst Rev. 2006: CD004974. Go to original source...
    50. Tricarico D, Varricchio A, D'Ambrosio S, Ascione E, Motta G. Prevention of recurrent upper respiratory tract infections in a community of cloistered nuns using a new immunostimulating bacterial lysate. A randomized, double-blind clinical trial. Arzneimittel-Forschung 2004; 54: 57-63. Go to original source...
    51. Petrunov B, Marinova S, Markova R, Nenkov P, Nikolaeva S, Nikolova M, Taskov H, Cvetanov J. Cellular and humoral systemic and mucosal immune responses stimulated in volunteers by an oral polybacterial immunomodulator, ,Dentavax". Int Immunopharmacol. 2006; 6: 1181-1193. Go to original source... Go to PubMed...
    52. Steurer-Stey C, Lagler L, Straub DA, Steurer J, Bachmann LM. Oral purified bacterial extracts in acute respiratory tract infections in childhood: a systematic quantitative review. Eur J. Pediatr. 2007; 166: 365-376. Go to original source... Go to PubMed...
    53. Gutierrez-Tarango MD, Berber A. Safety and efficacy of two courses of OM-85 BV in the pre-vention of respiratory tract infections in children during 12 months. Chest 2001; 119: 1742-1748. Go to original source... Go to PubMed...
    54. Bellanti J, Olivieri D, Serrano E. Ribosomal immunostimulation: assessment of studies eva-luating its clinical relevance in the prevention of upper and lower respiratory tract in-fections in children and adults. Biodrugs 2003; 17: 355-367. Go to original source... Go to PubMed...
    55. Soler M, Mutterlein R, Cozma G, Swiss-German OMSG. Double-blind study of OM-85 in pati-ents with chronic bronchitis or mild chronic obstructive pulmonary disease. Respiration 2007; 74: 26-32. Go to original source... Go to PubMed...
    56. Rozy A, Chorostowska-Wynimko J. Bacterial immunostimulants - mechanism of action and clinical application in respiratory diseases. Pneumonol Alergol Pol. 2008; 76: 353-359. Go to original source... Go to PubMed...
    57. Bauer HW, Alloussi S, Egger G, Blumlein HM, Cozma G, Schulman CC, Multicenter UTISG. A long-term, multicenter, double-blind study of an Escherichia coli extract (OM-89) in fe-male patients with recurrent urinary tract infections. Eur Urol. 2005; 47: 542-548. Go to original source... Go to PubMed...
    58. Schulman CC, Corbusier A, Michiels H, Taenzer HJ. Oral Immunotherapy of Recurrent Urinary Tract Infections - A Double-Blind Placebo-Controlled Multicenter Study. J Urol. 1993; 150: 917-921. Go to original source... Go to PubMed...
    59. Ha US, Cho Y-H. Immunostimulation with Escherichia coli extract: prevention of recurrent urinary tract infections. International J Antimicrob Agent. 2008; 31(Suppl 1): S63-67. Go to original source... Go to PubMed...
    60. Banche G, Allizond V, Mandras N, Garzaro M, Cavallo GP, Baldi C, Scutera S, Musso T, Roana J, Tullio V, et al. Improvement of clinical response in allergic rhinitis patients treated with an oral immunostimulating bacterial lysate: in vivo immunological effects. International J Immunopathol Pharmacol. 2007; 20: 129-138. Go to original source... Go to PubMed...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.